C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Buys New Holdings in BioNTech SE (NASDAQ:BNTX)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in shares of BioNTech SE (NASDAQ:BNTX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,810 shares of the company’s stock, valued at approximately $1,118,000.

A number of other large investors also recently modified their holdings of the company. Baillie Gifford & Co. grew its holdings in shares of BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after purchasing an additional 31,773 shares during the period. FMR LLC grew its stake in BioNTech by 797.8% during the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after buying an additional 5,598,190 shares during the period. Fred Alger Management LLC acquired a new stake in shares of BioNTech in the third quarter worth $59,485,000. DekaBank Deutsche Girozentrale raised its stake in shares of BioNTech by 12.6% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company’s stock valued at $56,886,000 after acquiring an additional 53,800 shares during the period. Finally, abrdn plc lifted its holdings in shares of BioNTech by 70.7% during the 4th quarter. abrdn plc now owns 385,668 shares of the company’s stock valued at $43,947,000 after acquiring an additional 159,676 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BNTX. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and increased their price target for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. TD Cowen lowered their target price on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research note on Tuesday, November 5th. BMO Capital Markets reissued an “outperform” rating on shares of BioNTech in a research report on Monday, December 2nd. Canaccord Genuity Group increased their price objective on shares of BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research report on Wednesday, November 27th. Finally, JPMorgan Chase & Co. reduced their target price on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 26th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $142.72.

BioNTech Trading Up 9.7 %

NASDAQ:BNTX opened at $122.78 on Friday. The company has a market cap of $29.44 billion, a PE ratio of -58.47 and a beta of 0.17. The business’s 50 day moving average is $117.26 and its two-hundred day moving average is $109.07. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.